Pyxis Oncology, Inc. (PYXS)
Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors. The company's antibody drug conjugate (ADC) product candidates comprise of PYX-201, an investigational novel ADC to treat NSCLC, breast cancer, and other solid tumors; PYX-202, an investigational novel ADC for treatment of SCLC, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational ADC for the treatment of acute myeloid leukemia and myeloid dysplastic syndrome. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
$224.62M
Dr. Lara S. Sullivan M.D., MBA
73.00
Cambridge, MA
Oct 08, 2021
-2.98
$-1.27
2.81
16.18
0.00%
-1.46
0.38
0.00
15.46
-21.40%
-23.18%
Similar stocks (9)
Terns Pharmaceuticals, Inc.
TERN
Inozyme Pharma, Inc.
INZY
Corvus Pharmaceuticals, Inc.
CRVS
HOOKIPA Pharma Inc.
HOOK
X4 Pharmaceuticals, Inc.
XFOR
PDS Biotechnology Corporation
PDSB
Elevation Oncology, Inc.
ELEV
Ocean Biomedical, Inc.
OCEA
eFFECTOR Therapeutics, Inc.
EFTR
ETF Exposure (21)
iShares Micro-Cap ETF
IWC
0.04614%
iShares Russell 2000 Value ETF
IWN
0.01302%
Vanguard Russell 2000 Index Fund
VTWO
0.01%
Vanguard Russell 2000 Value Index Fund
VTWV
0.01%
iShares Russell 2000 ETF
IWM
0.00654%
ProShares Ultra Russell2000
UWM
0.0025318441967060647%
ProShares UltraPro Russell2000
URTY
0.00124795367969069%
ProShares Hedge Replication ETF
HDG
0.0010555540236857706%
Dimensional U.S. Targeted Value ETF
DFAT
8.2459e-4%
Dimensional U.S. Small Cap ETF
DFAS
2.5807e-4%
Vanguard Balanced Index Fund Institutional Shares
VBAIX
0%
Vanguard Balanced Index Fund Admiral Shares
VBIAX
0%
Vanguard Balanced Index Fund
VBINX
0%
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Institutional Total Stock Market Index Fund Institutional Shares
VITNX
0%
Vanguard Institutional Total Stock Market Index Fund
VITPX
0%
Vanguard Total Stock Market Index Fund
VITSX
0%
Vanguard Russell 3000 Index Fund
VTHR
0%
Vanguard Total Stock Market Index Fund
VTI
0%
Vanguard Total Stock Market Index Fund
VTSAX
0%
Vanguard Extended Market Index Fund
VXF
0%
Similar stocks (9)
Terns Pharmaceuticals, Inc.
TERN
Inozyme Pharma, Inc.
INZY
Corvus Pharmaceuticals, Inc.
CRVS
HOOKIPA Pharma Inc.
HOOK
X4 Pharmaceuticals, Inc.
XFOR
PDS Biotechnology Corporation
PDSB
Elevation Oncology, Inc.
ELEV
Ocean Biomedical, Inc.
OCEA
eFFECTOR Therapeutics, Inc.
EFTR
ETF Exposure (21)
iShares Micro-Cap ETF
IWC
0.04614%
iShares Russell 2000 Value ETF
IWN
0.01302%
Vanguard Russell 2000 Index Fund
VTWO
0.01%
Vanguard Russell 2000 Value Index Fund
VTWV
0.01%
iShares Russell 2000 ETF
IWM
0.00654%
ProShares Ultra Russell2000
UWM
0.0025318441967060647%
ProShares UltraPro Russell2000
URTY
0.00124795367969069%
ProShares Hedge Replication ETF
HDG
0.0010555540236857706%
Dimensional U.S. Targeted Value ETF
DFAT
8.2459e-4%
Dimensional U.S. Small Cap ETF
DFAS
2.5807e-4%
Vanguard Balanced Index Fund Institutional Shares
VBAIX
0%
Vanguard Balanced Index Fund Admiral Shares
VBIAX
0%
Vanguard Balanced Index Fund
VBINX
0%
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Institutional Total Stock Market Index Fund Institutional Shares
VITNX
0%
Vanguard Institutional Total Stock Market Index Fund
VITPX
0%
Vanguard Total Stock Market Index Fund
VITSX
0%
Vanguard Russell 3000 Index Fund
VTHR
0%
Vanguard Total Stock Market Index Fund
VTI
0%
Vanguard Total Stock Market Index Fund
VTSAX
0%
Vanguard Extended Market Index Fund
VXF
0%